Clinigen Takes Aim At Unlicensed-To-Licensed Strategy With Quantum Buy

13 Sep 2017

• By John Davis

Extending its business in continental Europe, in niche generics and in the further development of unlicensed medicines are some of the drivers of Clinigen's latest proposed acquisition.

Target — Some patients need unlicensed medicines for their condition • Source: Shutterstock.

The UK pharmaceutical services company. Clinigen Group PLCis planning to acquire Quantum Pharma PLC in a cash-and-share deal valued at £150.3m ($199.5m), enlarging Clinigen's activities in the ethical supply of unlicensed medicines in the UK and continental Europe, and strengthening its role in commercializing medicine.

The interest of Clinigen in Quantum became public in the middle of last month, and the two AIM-listed companies have now agreed a scheme of arrangement for Clinigen to acquire Quantum, that would see Clinigen

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

06 May 2025

• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

05 May 2025

• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

In Brief: Sanofi Gains €10bn From Opella Sale

02 May 2025

• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.